Tsimikas, Sotirios

Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III

Pechlaner, R., Tsimikas, S., Yin, X., Willeit, P., Baig, F., Santer, P., Oberhollenzer, F., Egger, G., Witztum, J. L., Alexander, V. J., et al. (2017) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 171

Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)

Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., et al. (2025) · American Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 169

Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice

Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S. (2008) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 156

The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity

Tsimikas, S., & Witztum, J. L. (2008) · Current Opinion in Lipidology

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 138

Targeted Iron Oxide Particles for In Vivo Magnetic Resonance Detection of Atherosclerotic Lesions With Antibodies Directed to Oxidation-Specific Epitopes

Briley-Saebo, K. C., Cho, Y. S., Shaw, P. X., Ryu, S. K., Mani, V., Dickson, S., Izadmehr, E., Green, S., Fayad, Z. A., & Tsimikas, S. (2011) · Journal of the American College of Cardiology

Characterization and Applications of Magnetic NanoparticlesAtherosclerosis and Cardiovascular Diseases

Cited by 128

Integrated Assessment of the Clinical Performance of GalNAc 3 -Conjugated 2′- O -Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

Crooke, S. T., Baker, B. F., Xia, S., Yu, R. Z., Viney, N. J., Wang, Y., Tsimikas, S., & Geary, R. S. (2019) · Nucleic Acid Therapeutics

RNA Interference and Gene DeliveryDNA and Nucleic Acid Chemistry

Cited by 127

Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice

Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 124

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size

Tsimikas, S., Fazio, S., Viney, N. J., Xia, S., Witztum, J. L., & Marcovina, S. M. (2018) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 109

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results

Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 103

Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients

Moriarty, P. M., Varvel, S. A., Gordts, P. L. S. M., McConnell, J. P., & Tsimikas, S. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 89

Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia

Alexander, V. J., Karwatowska-Prokopczuk, E., Prohaska, T. A., Li, L., Geary, R. S., Gouni-Berthold, I., Oral, E. A., Hegele, R. A., Stroes, E. S. G., Witztum, J. L., et al. (2024) · New England Journal of Medicine

Pancreatitis Pathology and TreatmentLipid metabolism and disorders

Cited by 85

Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis

Arsenault, B. J., Loganath, K., Girard, A., Botezatu, S., Zheng, K. H., Tzolos, E., Abdoun, K., Tastet, L., Capoulade, R., Côté, N., et al. (2024) · JAMA Cardiology

Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment Approaches

Cited by 80

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., et al. (2025) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 78

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

Marston, N. A., Bergmark, B. A., Alexander, V. J., Prohaska, T. A., Kang, Y. M., Moura, F. A., Zimerman, A., Waldman, E., Weinland, J., Murphy, S. A., et al. (2026) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 62

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance

Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., et al. (2019) · Journal of Lipid Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 59

Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen

Karwatowska-Prokopczuk, E., Clouet-Foraison, N., Xia, S., Viney, N. J., Witztum, J. L., Marcovina, S. M., & Tsimikas, S. (2021) · Atherosclerosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 27